Simulations Plus – Consensus indicates potential of 21.3% upside

Simulations Plus with ticker code (SLP) now have a total of 4 analysts who cover the share. The consensus rating is ‘Strong_Buy’. The range between the high target price and the low target price is between 95 and 76 with an average TP of 82.75. With stocks previously closing at 68.2, this points to a potential upside of 21.3%. The 50-day moving average is now at 62.47 and the 200-day moving average is now at 63.58. The company’s market capitalization is $ 1,459 million. Visit the company website at: http://www.simulations-plus.com

Simulations Plus develops software for drug discovery and development for mechanistic modeling and simulation as well as the prediction of properties of molecules using technologies based on artificial intelligence and machine learning worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug interactions of compounds administered to humans and animals; DDDPlus, which simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also offers PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyzes and generate the results necessary to meet regulatory requirements for non-compartmental analysis and compartmentalized PK modeling; ADMET Predictor, a chemistry-based computer program that uses molecular structures as inputs and predicts their properties; and MedChem Designer, a program for drawing molecules or sketcher. In addition, it offers KIWI, a cloud-based web application for organizing, processing, managing and communicating the amounts of data and results generated by pharmacologists and scientists during the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for the analysis of non-alcoholic fatty liver disease; RENAsym for the investigation and prediction of drug-induced or acute kidney damage; IPFsym, a software tool used to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. The company also provides contract research services for population modeling and simulation; and clinical pharmacological advisory services to support regulatory filings. It serves pharmaceutical, biotechnology, agrochemical, cosmetic and food companies as well as academic and government agencies. The company was founded in 1996 and is headquartered in Lancaster, California.